# To Evaluate the Pharmacokinetics and Safety of AD-208

> **NCT04214808** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 24 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** AD-208
- **DRUG:** Avodart Soft Capsule 0.5mg

## Key facts

- **NCT ID:** NCT04214808
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-03
- **Primary completion:** 2020-02-04
- **Final completion:** 2020-05-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214808, "To Evaluate the Pharmacokinetics and Safety of AD-208". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04214808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*